OakChart

Estrella Immunopharma Inc

ESLAHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.7939+0.0467 (6.25%)
2026-11-11 23:24 CET
Market cap
32.50 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-10.01 USD m
Free cash flow, TTM
-9.38 USD m
EPS diluted, TTM
-0.25
P/E
-
Compare

Price

ESLA against its 20, 50 and 200-day averages
2050200earnings
0.501.001.5031.6M63.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ESLAclose 0.7920-day 0.6150-day 0.55200-day 0.970.7952w low

70.7% under the 52-week high of 2.71 on 11 Nov 2025. 52-week low 0.24 on 19 Oct 2026. Last 15 sessions, 226.7% high to low

Volume 0.39× normal · the line is the 50-bar volume average

Profile

ESLA
52-week range, 22% of the way up
0.242.71

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.

IPOSep 14, 2021
Beta0.86
ATR, 14d0.14
Rel volume0.39
Short float5.39%
Insider own60.42%
Inst own10.99%

Snapshot

6 groups

Valuation

Index-
Market Cap34.53M
Enterprise Value34.38M
Income-10.01M
Sales0.00M
Book/sh-0.17
Cash/sh0.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOSep 14, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C230.21
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.20
Current Ratio0.20
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.25
EPS next Y-
EPS next Q-0.08
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y-27.10% -70.08%
Sales past 3/5Y- -
EPS Y/Y TTM24.03%
Sales Y/Y TTM-
EPS Q/Q65.04%
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.0.00% -

Ownership

Insider Own60.42%
Insider Trans0.00%
Inst Own10.99%
Inst Trans-1.32%
ROA-416.74%
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2030.41%
SMA5044.38%
SMA200-18.15%
Trades-

Technical

Shs Outstand43.03M
Shs Float17.22M
Short Float5.39%
Short Ratio0.48
Short Interest0.93M
52W High2.71 -70.70%
52W Low0.24 230.79%
Volatility26.87% 37.77%
ATR (14)0.14
RSI (14)60.16
Beta0.86
Rel Volume0.39
Avg Volume1.94M
Volume747,696

Performance

Perf Week79.01%
Perf Month152.83%
Perf Quarter9.56%
Perf Half Y-33.84%
Perf YTD-49.11%
Perf Year-68.37%
Perf 3Y-38.53%
Perf 5Y-91.97%
Perf 10Y-
Recom1.00
Target Price12.00
Prev Close0.75
Price0.79
Change %6.25%

Peers

Mkt cap
TickerCompanyMkt cap
MRKRMarker Therapeutics Inc15.84M
ACETAdicet Bio Inc27.99M
CRBUCaribou Biosciences Inc42.21M
ALLOAllogene Therapeutics Inc311.85M
AUTLAutolus Therapeutics plc ADR328.71M
TCRXTscan Therapeutics Inc12.58M
NKTXNkarta Inc106.12M
CABACabaletta Bio Inc312.79M
KYTXKyverna Therapeutics Inc316.63M
FATEFate Therapeutics Inc195.12M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Liu ChengCEOAug 25 '26Option Exercise0.81100,00081,500397,437Aug 26 07:23 PM
Xu JiandongChief Financial OfficerAug 18 '26Option Exercise0.81100,00081,500365,488Aug 25 09:55 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 66

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-0.050-0.050-0.0540.000.001
2026Q12026-06-03-0.050--0.0540.00--
2025Q42026-02-25-0.140-0.180-0.0160.000.001
2025Q32025-12-03-0.190-0.187-0.1290.000.001
2025Q22025-09-03-0.068-0.070-0.1530.000.001
2025Q12025-05-28-0.070-0.110-0.0580.00-1
2026Q3---0.080--0.001
2026Q4---0.070--0.001
2027Q1---0.116---1
2027Q2---0.110---1
2027Q3---0.053--22.741
2027Q4---0.042--23.731
2028Q1---0.035--25.711
2028Q2---0.022--26.691
2028Q3---0.070--25.711
2028Q4---0.045--26.691

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-021000.000.000.00
2026Q3S2026-07-141000.000.000.00
2026Q3S2025-12-031000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00
2026Q3S2025-11-021000.000.000.00
2026Q3S2025-11-011000.000.000.00

Estimate history

EPS, annual-0.042-0.243-0.355-0.2536
Period202120242025TTM
EPS, quarterly-1.777-0.029-0.058-0.153-0.129-0.016-0.054-0.054
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000
Period202120242025TTM
Sales, quarterly00000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual5.8536.19437.97143.034
Period202120242025MRQ
Shares, quarterly35.20136.19436.16637.06637.76637.97142.66543.034
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2024FY2021FY
Total Revenue0.000.000.000.00-0.00
Cost of Goods Sold Incl. D&A0.000.000.000.00-0.00
Gross Profit0.000.000.000.00-0.00
Selling, General and Administrative Excl. Other9.6813.068.857.31-0.18
Research and Development6.9810.255.724.11--
Other Operating Expense0.000.000.000.00-0.07
Operating Income-9.68-13.06-8.85-7.31--0.25
Interest Expense0.000.000.000.00-0.00
Unusual Expense0.330.000.000.00-0.00
Net Income Before Taxes-10.01-13.06-8.85-7.31--0.25
Income Taxes-0.000.000.000.00-0.00
Consolidated Net Income-10.01-13.06-8.85-7.31--0.25
Net Income From Continuing Operations-10.01-13.06-8.85-7.31--0.25
Net Income-10.01-13.06-8.85-7.31--0.25
EPS (Recurring)-0.23-0.35-0.24-0.27--0.04
EPS (Basic, Before Extraordinaries)-0.25-0.35-0.24-0.27--0.04
EPS (Diluted)-0.25-0.35-0.24-0.27--0.04
EBITDA-9.68-13.06-8.85-7.31--0.25
Non-Operating Income (Expense)0.000.000.000.00-0.00
Other After Tax Adjustments0.000.000.000.00-0.00
Stock Option Compensation Expense0.560.490.680.94--
Shares Outstanding43.0337.9736.1936.61-5.85
Market Capitalization32.5032.5043.4138.20-47.00

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q5
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other2.082.180.614.805.542.101.053.38
Research and Development1.401.400.034.154.661.410.032.83
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.08-2.18-0.61-4.80-5.54-2.10-1.05-3.38
Interest Expense0.000.000.000.000.000.000.00-
Unusual Expense0.220.110.000.000.000.000.000.00
Net Income Before Taxes-2.31-2.29-0.61-4.80-5.54-2.10-1.05-3.38
Income Taxes0.000.00-0.000.000.000.000.000.00
Consolidated Net Income-2.31-2.29-0.61-4.80-5.54-2.10-1.05-3.38
Net Income From Continuing Operations-2.31-2.29-0.61-4.80-5.54-2.10-1.05-3.38
Net Income-2.31-2.29-0.61-4.80-5.54-2.10-1.05-3.38
EPS (Recurring)-0.05-0.05-0.02-0.13-0.15-0.06-0.03-0.09
EPS (Basic, Before Extraordinaries)-0.05-0.05-0.02-0.13-0.15-0.06-0.03-0.09
EPS (Diluted)-0.05-0.05-0.02-0.13-0.15-0.06-0.03-0.09
EBITDA-2.08-2.18-0.61-4.80-5.54-2.10-1.05-3.38
Non-Operating Income (Expense)0.000.000.000.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.150.150.120.150.130.130.340.00
Shares Outstanding43.0342.6737.9737.7737.0736.1736.1935.20
Market Capitalization32.5045.2358.9142.6334.7233.5343.4142.20

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2024FY2021FY
Cash & Short Term Investments1.380.924.17-0.48
Short Term Receivables0.000.000.00-0.00
Inventories0.000.000.00-0.00
Other Current Assets0.290.720.29-0.14
Total Current Assets1.681.644.45-0.62
Net Property, Plant & Equipment0.000.000.00-0.00
Total Investments and Advances0.000.000.00-45.19
Intangible Assets0.000.000.00-0.00
Other Assets1.501.500.00-0.00
Total Assets3.183.144.45-45.80
Short Term Debt Incl. Current Port. of LT Debt0.000.000.00-0.00
Accounts Payable0.550.000.00-0.00
Income Tax Payable0.005E-050.04--
Other Current Liabilities12.993.000.14-0.07
Total Current Liabilities13.543.000.18-0.07
Long Term Debt0.000.000.00-0.00
Provision for Risks Charges0.000.000.00-0.00
Other Liabilities0.000.000.00-1.55
Total Liabilities13.543.000.18-1.62
Non-Equity Reserves0.000.000.00-0.00
Preferred Stock - Carrying Value0.000.000.00-0.00
Common Equity-10.370.144.27-44.18
Total Shareholders Equity-10.370.144.27-44.18
Accumulated Minority Interest0.000.000.00-0.00
Total Equity-10.370.144.27-44.18
Total Liabilities & Stockholders Equity3.183.144.45-45.80
Book Value Per Share-0.270.000.12-7.55
Tangible Book Value Per Share-0.270.000.12-7.55
Price to Book Ratio-4.3356.604.52-1.31
Return on Assets-413.55----
Return on Invested Capital--6,160.16-171.09--0.56
Quick Ratio0.120.5524.65-8.42
Current Ratio0.120.5524.65-8.42

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2024FY2021FY
Net Income-10.01-13.06-4.43-7.31--0.25
Other Funds (Non Cash)0.960.660.431.19--0.00
Funds from Operations-9.05-12.41-3.99-6.12--0.25
Extraordinary Item0.000.000.000.00-0.00
Changes in Working Capital-0.3310.620.88-9.95--0.07
Income Taxes Payable--5E-05-0.04---
Cash from Operating Activities-9.38-1.79-3.11-16.07--0.32
Capital Expenditures0.000.000.000.00-0.00
Net Assets From Acquisitions0.000.000.000.00-0.00
Sale of Fixed Assets and Businesses0.000.000.000.00-0.00
Purchase or Sale of Investments0.000.000.000.00--45.19
Purchase of Investments0.000.000.000.00--45.19
Sale Or Maturity of Investments0.000.000.000.00-0.00
Other Uses0.000.000.00-0.11-0.00
Other Sources0.000.000.005.07-0.00
Cash from Investing Activities0.000.000.004.96--45.19
Cash Dividends Paid0.000.000.000.00-0.00
Change in Capital Stock9.052.37-0.1313.59-46.87
Repurchase of Common Pref Stock0.00-0.03-0.21-5.43--0.03
Sale of Common Pref Stock9.052.400.0819.02-46.89
Proceedsfrom Stock Options9.052.400.0819.02-46.89
Issuance or Reduction of Debt, Net0.000.000.000.00-0.00
Change in Long Term Debt0.000.000.000.00-0.00
Issuance of Long Term Debt0.000.000.000.00-0.00
Reduction of Long Term Debt0.000.000.000.00-0.00
Net Financing Active Other Cash Flow-0.84-0.120.00-0.80--0.89
Other Financing Activities Uses-0.84-0.120.00-1.53--0.89
Cash from Financing Activities8.212.25-0.1312.79-45.98
Net Change in Cash-1.170.47-3.251.69-0.48
Free Cash Flow-9.38-1.79-3.11-16.07--0.32
Preferred Dividends (Cash Flow)-0.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.00-0.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.151.931.381.631.320.42
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.680.230.290.400.160.52
Total Current Assets1.822.161.682.021.480.94
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.001.501.501.501.501.50
Total Assets1.823.663.183.522.982.44
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.010.010.550.010.010.00
Income Tax Payable--0.000.000.005E-05
Other Current Liabilities9.258.9112.9913.359.074.28
Total Current Liabilities9.268.9313.5413.369.084.28
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities9.268.9313.5413.369.084.28
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-7.43-5.27-10.37-9.84-6.09-1.83
Total Shareholders Equity-7.43-5.27-10.37-9.84-6.09-1.83
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-7.43-5.27-10.37-9.84-6.09-1.83
Total Liabilities & Stockholders Equity1.823.663.183.522.982.44
Book Value Per Share-0.17-0.12-0.27-0.26-0.16-0.05
Tangible Book Value Per Share-0.17-0.12-0.27-0.26-0.16-0.05
Price to Book Ratio-4.33-3.88-5.99-6.99-18.96236.48
Return on Assets-416.74-434.36-413.55-371.99-324.86-189.25
Return on Equity------314.60
Quick Ratio0.200.240.120.150.160.22
Current Ratio0.200.240.120.150.160.22

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.31-2.29-0.61-4.80-5.54-2.10
Other Funds (Non Cash)0.370.260.120.220.160.16
Funds from Operations-1.94-2.04-0.49-4.58-5.39-1.95
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.16-4.660.323.854.971.48
Income Taxes Payable--0.000.00--
Cash from Operating Activities-1.78-6.70-0.18-0.73-0.41-0.47
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4E-068.000.001.051.35-0.03
Repurchase of Common Pref Stock0.000.000.000.000.00-0.03
Sale of Common Pref Stock4E-068.000.001.051.350.00
Proceedsfrom Stock Options0.008.000.001.051.350.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.76-0.06-0.01-0.040.00
Other Financing Activities Uses0.00-0.76-0.06-0.01-0.040.00
Cash from Financing Activities4E-067.24-0.061.041.31-0.03
Net Change in Cash-1.780.54-0.240.310.90-0.50
Free Cash Flow-1.78-6.70-0.18-0.73-0.41-0.47
Price to Free Cash Flow----2.882.75

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.39%0.9M17.2M1.75M
2026-10-153.48%0.6M17.2M1.33M
2026-09-301.24%0.2M17.2M39.80K
2026-09-150.89%0.2M17.2M38.03K
2026-08-310.69%0.1M16.9M39.78K
2026-08-140.36%0.1M17.1M38.57K
2026-07-310.28%0.0M17.0M40.51K
2026-07-150.32%0.1M17.0M39.11K
2026-06-300.53%0.1M17.0M79.69K
2026-06-150.67%0.1M17.0M84.57K
2026-05-290.49%0.1M16.7M83.90K
2026-05-150.56%0.1M17.0M86.36K
2026-04-300.88%0.1M16.8M200.18K
2026-04-151.58%0.3M16.8M209.02K
2026-03-313.87%0.6M16.2M175.40K
2026-03-134.05%0.7M16.2M179.04K
2026-02-274.00%0.6M16.0M197.05K
2026-02-134.55%0.7M16.0M220.30K
2026-01-305.94%0.9M15.9M190.49K
2026-01-156.64%0.9M13.0M256.14K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-033Initial statement of beneficial ownership of securities2026-10-25SEC
2026-10-298-KCurrent report2026-10-25SEC
2026-09-088-KCurrent report2026-09-01SEC
2026-08-264Statement of changes in beneficial ownership of securities2026-08-25SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-218-KCurrent report2026-08-17SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-06-308-KCurrent report2026-06-29SEC
2026-05-27DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-29SEC
2026-05-1810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-18NT 10-Q2026-03-31SEC
2026-05-15SCHEDULE 13GSEC
2026-04-3010-K/A2025-12-31SEC
2026-04-294Statement of changes in beneficial ownership of securities2025-09-11SEC
2026-03-1810-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-13424B3SEC
2026-01-23EFFECTEffectiveness filing by commission orderSEC
2026-01-22CORRESPSEC
2026-01-22S-1/ASEC
2026-01-16S-1/ASEC
2026-01-138-KCurrent report2026-01-07SEC
2026-01-068-KCurrent report2026-01-05SEC
2026-01-06424B5SEC
2025-12-29UPLOADUpload SubmissionSEC
2025-12-22S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2025-12-048-KCurrent report2025-12-04SEC
2025-11-1210-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-11-068-KCurrent report2025-11-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARMISTICE CAPITAL, LLC9.24%
VANGUARD CAPITAL MANAGEMENT LLC0.97%
GEODE CAPITAL MANAGEMENT, LLC0.32%
VANGUARD FIDUCIARY TRUST CO0.15%
BlackRock, Inc.0.12%
STATE STREET CORP0.10%
RENAISSANCE TECHNOLOGIES LLC0.09%
NORTHERN TRUST CORP0.08%
US BANCORP \DE\0.05%
CITIGROUP INC0.01%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.62%
VANGUARD EXTENDED MARKET INDEX FUND0.34%
Fidelity Extended Market Index Fund0.18%
iShares Micro-Cap ETF0.12%
Fidelity Series Total Market Index Fund0.06%
Fidelity Total Market Index Fund0.04%
1290 VT Micro Cap Portfolio0.01%
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. ESLA. Cached 15 minutes.

Some panels did not load: ratings.